Heterogeneity of mammary lesions represent molecular differences
详细信息 查看全文
- 作者：Ruria Namba (1)
Jeannie E Maglione (2)
Ryan R Davis (1)
Colin A Baron (1)
Stephenie Liu (1)
Condie E Carmack (3)
Lawrence JT Young (2)
Alexander D Borowsky (1) (2)
Robert D Cardiff (1) (2)
Jeffrey P Gregg (1) - 刊名：BMC Cancer
- 出版年：2006
- 出版时间：December 2006
- 年：2006
- 卷：6
- 期：1
- 全文大小：1311KB
- 参考文献：1. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. / Cell 1990, 61 (5) : 759鈥?67. CrossRef
2. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG, Kuo WL, Ljung BM, Chew K, Myambo K, Miranda M, Krig S, Garbe J, Stampfer M, Yaswen P, Gray JW, Lockett SJ: In situ analyses of genome instability in breast cancer. / Nat Genet 2004, 36 (9) : 984鈥?88. CrossRef
3. Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, Ljung BM, Waldman FM: Patterns of chromosomal alterations in breast ductal carcinoma in situ. / Clin Cancer Res 2004, 10 (15) : 5160鈥?167. CrossRef
4. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC: Gene expression profiles of human breast cancer progression. / Proc Natl Acad Sci U S A 2003, 100 (10) : 5974鈥?979. CrossRef
5. Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Welzl G, Hofler H, Werner M: Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. / Int J Cancer 2000, 85 (1) : 82鈥?6. CrossRef
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. / Nature 2000, 406 (6797) : 747鈥?52. CrossRef
7. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. / Proc Natl Acad Sci U S A 2001, 98 (19) : 10869鈥?0874. CrossRef
8. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. / Nature 2002, 415 (6871) : 530鈥?36. CrossRef
9. Mallon E, Osin P, Nasiri N, Blain I, Howard B, Gusterson B: The basic pathology of human breast cancer. / J Mammary Gland Biol Neoplasia 2000, 5 (2) : 139鈥?63. CrossRef
10. Shoker BS, Sloane JP: DCIS grading schemes and clinical implications. / Histopathology 1999, 35 (5) : 393鈥?00. CrossRef
11. Maglione JE, McGoldrick ET, Young LJ, Namba R, Gregg JP, Liu L, Moghanaki D, Ellies LG, Borowsky AD, Cardiff RD, MacLeod CL: Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes. / Mol Cancer Ther 2004, 3 (8) : 941鈥?53.
12. Namba R, Maglione JE, Young LJ, Borowsky AD, Cardiff RD, MacLeod CL, Gregg JP: Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ. / Mol Cancer Res 2004, 2 (8) : 453鈥?63.
13. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE: The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. / Oncogene 2000, 19 (8) : 968鈥?88. CrossRef
14. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL: Transgenic Polyoma middle-T mice model premalignant mammary disease. / Cancer Res 2001, 61 (22) : 8298鈥?305.
15. Namba R, Young LJ, Maglione JE, McGoldrick ET, Liu S, Wurz GT, DeGregorio MW, Borowsky AD, MacLeod CL, Cardiff RD, Gregg JP: Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of DCIS. / Breast Cancer Res 2005, 7 (6) : R881鈥?89. CrossRef
16. RepeatMasker [http://www.repeatmasker.org]
17. Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, Lefkowitz SM, Ziman M, Schelter JM, Meyer MR, Kobayashi S, Davis C, Dai H, He YD, Stephaniants SB, Cavet G, Walker WL, West A, Coffey E, Shoemaker DD, Stoughton R, Blanchard AP, Friend SH, Linsley PS: Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. / Nat Biotechnol 2001, 19 (4) : 342鈥?47. CrossRef
18. Agilent Technologies [http://www.chem.agilent.com]
19. Barrett MT, Scheffer A, Ben-Dor A, Sampas N, Lipson D, Kincaid R, Tsang P, Curry B, Baird K, Meltzer PS, Yakhini Z, Bruhn L, Laderman S: Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. / Proc Natl Acad Sci U S A 2004, 101 (51) : 17765鈥?7770. CrossRef
20. ErmineJ software [http://microarray.cu-genome.org/ermineJ/]
21. Lee HK, Braynen W, Keshav K, Pavlidis P: ErmineJ: tool for functional analysis of gene expressiono data sets. / BMC Bioinformatics 2005, 6: 269. CrossRef
22. UCSC Genome Browser [http://genome.ucsc.edu/cgi-bin/hgGateway]
23. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW: Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. / Am J Pathol 2003, 163 (5) : 2113鈥?126.
24. Hodgson JG, Malek T, Bornstein S, Hariono S, Ginzinger DG, Muller WJ, Gray JW: Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. / Cancer Res 2005, 65 (21) : 9695鈥?704. CrossRef
25. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. / Nature 1997, 390 (6656) : 175鈥?79. CrossRef
26. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM: Activation of RalA is critical for Ras-induced tumorigenesis of human cells. / Cancer Cell 2005, 7 (6) : 533鈥?45. CrossRef
27. Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP: Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. / Clin Cancer Res 2005, 11 (9) : 3184鈥?190. CrossRef
28. Grimm SL, Rosen JM: The role of C/EBPbeta in mammary gland development and breast cancer. / J Mammary Gland Biol Neoplasia 2003, 8 (2) : 191鈥?04. CrossRef
29. Shi B, Vinyals A, Alia P, Broceno C, Chen F, Adrover M, Gelpi C, Price JE, Fabra A: Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development. / Int J Biochem Cell Biol 2006, 38 (4) : 544鈥?62. CrossRef
30. Tamiolakisl D, Venizelos I, Lambropoulou M, Jivannakis T, Seliniotakis E, Tsikouras P, Limberis V, Tsalkidis A, Papadopoulos N: Gains and losses of HLA class II (DR) and CD4 in atypical hyperplasia, carcinoma in situ and infiltrating ductal carcinoma of the breast. / Acta Medica (Hradec Kralove) 2004, 47 (4) : 257鈥?62.
31. Eckerdt F, Yuan J, Strebhardt K: Polo-like kinases and oncogenesis. / Oncogene 2005, 24 (2) : 267鈥?76. CrossRef
32. Kinch MS, Carles-Kinch K: Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. / Clin Exp Metastasis 2003, 20 (1) : 59鈥?8. CrossRef
33. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, Dynlacht BD: E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. / Genes Dev 2002, 16 (2) : 245鈥?56. CrossRef
34. Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, Wong S, Lasaga J, Shen MR, Yu S, Xu W, Hitoshi Y, Bogenberger J, Nor JE, Payan DG, Lorens JB: Multiple roles for the receptor tyrosine kinase axl in tumor formation. / Cancer Res 2005, 65 (20) : 9294鈥?303. CrossRef
35. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. / Nat Genet 2003, 33 (1) : 49鈥?4. CrossRef
36. Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET: Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. / Cancer Res 2004, 64 (17) : 5973鈥?981. CrossRef
37. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, Kurek R, Neubauer HJ: Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. / Cancer Res 2006, 66 (10) : 5278鈥?286. CrossRef
38. Ritland SR, Rowse GJ, Chang Y, Gendler SJ: Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. / Cancer Res 1997, 57 (16) : 3520鈥?525.
39. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A: Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. / Cancer Res 2004, 64 (1) : 64鈥?1. CrossRef
40. Jonsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang J, Ward MR, Greshock JD, Luts L, Olsson H, Rahman N, Stratton M, Ringner M, Borg A, Weber BL: Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. / Cancer Res 2005, 65 (17) : 7612鈥?621.
41. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schroder W, Tietze L: Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. / J Pathol 2001, 193 (1) : 40鈥?7. CrossRef
42. Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, Gelman R, Brennan C, Polyak K: Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. / Cancer Res 2006, 66 (8) : 4065鈥?078. CrossRef
43. O'Connell P: Genetic and cytogenetic analyses of breast cancer yield different perspectives of a complex disease. / Breast Cancer Res Treat 2003, 78 (3) : 347鈥?57. CrossRef
44. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, / et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. / Science 1989, 244 (4905) : 707鈥?12. CrossRef
45. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D, Albertson DG: Breast tumor copy number aberration phenotypes and genomic instability. / BMC Cancer 2006, 6: 96. CrossRef
46. Sutherland RL, Musgrove EA: Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. / Breast Cancer Res 2002, 4 (1) : 14鈥?7. CrossRef
47. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW: Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. / Cancer Cell 2006, 9 (1) : 13鈥?2. CrossRef
48. Reddy HK, Mettus RV, Rane SG, Grana X, Litvin J, Reddy EP: Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. / Cancer Res 2005, 65 (22) : 10174鈥?0178. CrossRef
49. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y, Gardner H, Kiyokawa H, Harris LN, Stal O, Sicinski P: Requirement for CDK4 kinase function in breast cancer. / Cancer Cell 2006, 9 (1) : 23鈥?2. CrossRef
50. Liu G, Lozano G: p21 stability: linking chaperones to a cell cycle checkpoint. / Cancer Cell 2005, 7 (2) : 113鈥?14. CrossRef
51. Weiss RH: p21Waf1/Cip1 as a therapeutic target in breast and other cancers. / Cancer Cell 2003, 4 (6) : 425鈥?29. CrossRef
52. Yuste L, Montero JC, Esparis-Ogando A, Pandiella A: Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. / Cancer Res 2005, 65 (15) : 6801鈥?810. CrossRef
53. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, Roughley PJ, Murphy LC, Watson PH: Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. / Clin Cancer Res 2003, 9 (1) : 207鈥?14.
54. Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB: Downregulation of gelsolin correlates with the progression to breast carcinoma. / Breast Cancer Res Treat 2001, 65 (1) : 11鈥?1. CrossRef
55. Meraldi P, Honda R, Nigg EA: Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. / Embo J 2002, 21 (4) : 483鈥?92. CrossRef
56. Hoque A, Carter J, Xia W, Hung MC, Sahin AA, Sen S, Lippman SM: Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. / Cancer Epidemiol Biomarkers Prev 2003, 12 (12) : 1518鈥?522.
57. Miyoshi Y, Iwao K, Egawa C, Noguchi S: Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. / Int J Cancer 2001, 92 (3) : 370鈥?73. CrossRef
58. Feng Y, Walsh CA: Mitotic spindle regulation by Nde1 controls cerebral cortical size. / Neuron 2004, 44 (2) : 279鈥?93. CrossRef
59. Castro A, Bernis C, Vigneron S, Labbe JC, Lorca T: The anaphase-promoting complex: a key factor in the regulation of cell cycle. / Oncogene 2005, 24 (3) : 314鈥?25. CrossRef
60. Peters JM: The anaphase-promoting complex: proteolysis in mitosis and beyond. / Mol Cell 2002, 9 (5) : 931鈥?43. CrossRef
61. van Vugt MA, Medema RH: Getting in and out of mitosis with Polo-like kinase-1. / Oncogene 2005, 24 (17) : 2844鈥?859. CrossRef
62. Myer DL, Bahassi el M, Stambrook PJ: The Plk3-Cdc25 circuit. / Oncogene 2005, 24 (2) : 299鈥?05. CrossRef
63. Coussens LM, Werb Z: Inflammation and cancer. / Nature 2002, 420 (6917) : 860鈥?67. CrossRef
64. Philip M, Rowley DA, Schreiber H: Inflammation as a tumor promoter in cancer induction. / Semin Cancer Biol 2004, 14 (6) : 433鈥?39. CrossRef
65. Bissell MJ, Radisky D: Putting tumours in context. / Nat Rev Cancer 2001, 1 (1) : 46鈥?4. CrossRef
66. Zeh HJ 3rd, Lotze MT: Addicted to death: invasive cancer and the immune response to unscheduled cell death. / J Immunother 2005, 28 (1) : 1鈥?. CrossRef
67. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. / Nature 2001, 410 (6824) : 50鈥?6. CrossRef
68. Lin EY, Pollard JW: Macrophages: modulators of breast cancer progression. / Novartis Found Symp 2004, 256: 158鈥?8; discussion 168鈥?2, 259鈥?9. CrossRef
69. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR, Muller WJ, Moses HL: Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. / Cancer Res 2005, 65 (6) : 2296鈥?302. CrossRef
70. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL: Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. / Cancer Res 2004, 64 (24) : 9002鈥?011. CrossRef
71. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL: Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. / J Clin Invest 2002, 109 (12) : 1551鈥?559.
72. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, Flick MJ, Witte DP, Dano K, Degen JL: Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. / Oncogene 1998, 16 (24) : 3097鈥?104. CrossRef
73. Lee WP, Wen Y, Varnum B, Hung MC: Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. / Oncogene 2002, 21 (3) : 329鈥?36. CrossRef
74. Schwartzberg PL: Immunology. Tampering with the immune system. / Science 2001, 293 (5528) : 228鈥?29. CrossRef
75. Phan RT, Dalla-Favera R: The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. / Nature 2004, 432 (7017) : 635鈥?39. CrossRef
76. Bouma-ter Steege JC, Baeten CI, Thijssen VL, Satijn SA, Verhoeven IC, Hillen HF, Wagstaff J, Griffioen AW: Angiogenic profile of breast carcinoma determines leukocyte infiltration. / Clin Cancer Res 2004, 10 (21) : 7171鈥?178. CrossRef
77. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G: Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. / Cancer Res 1996, 56 (5) : 1111鈥?117.
78. Cid MC, Schnaper HW, Kleinman HK: Estrogens and the vascular endothelium. / Ann N Y Acad Sci 2002, 966: 143鈥?57. CrossRef
79. Tsuchiya Y, Nakajima M, Yokoi T: Cytochrome P450-mediated metabolism of estrogens and its regulation in human. / Cancer Lett 2005, 227 (2) : 115鈥?24. CrossRef
80. Kalaitzidis D, Gilmore TD: Transcription factor cross-talk: the estrogen receptor and NF-kappaB. / Trends Endocrinol Metab 2005, 16 (2) : 46鈥?2. CrossRef
81. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH: Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. / Proc Natl Acad Sci U S A 2004, 101 (49) : 17126鈥?7131. CrossRef
82. Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, Giacalone PL, Chalbos D, Maudelonde T, Rochefort H, Pujol P: Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. / Oncogene 2002, 21 (7) : 1097鈥?107. CrossRef
83. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. / J Steroid Biochem Mol Biol 2000, 74 (5) : 311鈥?17. CrossRef
84. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/6/275/prepub - 作者单位：Ruria Namba (1)
Jeannie E Maglione (2)
Ryan R Davis (1)
Colin A Baron (1)
Stephenie Liu (1)
Condie E Carmack (3)
Lawrence JT Young (2)
Alexander D Borowsky (1) (2)
Robert D Cardiff (1) (2)
Jeffrey P Gregg (1)
1. Department of Pathology and Laboratory Medicine, School of Medicine, University of California at Davis, 95817, Sacramento, CA, USA
2. Center for Comparative Medicine, University of California at Davis, 95616, Davis, CA, USA
3. Agilent Technologies, Deer Creek Rd, 94304, Palo Alto, CA, USA - ISSN：1471-2407
文摘
Background Human breast cancer is a heterogeneous disease, histopathologically, molecularly and phenotypically. The molecular basis of this heterogeneity is not well understood. We have used a mouse model of DCIS that consists of unique lines of mammary intraepithelial neoplasia (MIN) outgrowths, the premalignant lesion in the mouse that progress to invasive carcinoma, to understand the molecular changes that are characteristic to certain phenotypes. Each MIN-O line has distinguishable morphologies, metastatic potentials and estrogen dependencies. Methods We utilized oligonucleotide expression arrays and high resolution array comparative genomic hybridization (aCGH) to investigate whole genome expression patterns and whole genome aberrations in both the MIN-O and tumor from four different MIN-O lines that each have different phenotypes. From the whole genome analysis at 35 kb resolution, we found that chromosome 1, 2, 10, and 11 were frequently associated with whole chromosome gains in the MIN-Os. In particular, two MIN-O lines had the majority of the chromosome gains. Although we did not find any whole chromosome loss, we identified 3 recurring chromosome losses (2F1-2, 3E4, 17E2) and two chromosome copy number gains on chromosome 11. These interstitial deletions and duplications were verified with a custom made array designed to interrogate the specific regions at approximately 550 bp resolution. Results We demonstrated that expression and genomic changes are present in the early premalignant lesions and that these molecular profiles can be correlated to phenotype (metastasis and estrogen responsiveness). We also identified expression changes associated with genomic instability. Progression to invasive carcinoma was associated with few additional changes in gene expression and genomic organization. Therefore, in the MIN-O mice, early premalignant lesions have the major molecular and genetic changes required and these changes have important phenotypic significance. In contrast, the changes that occur in the transition to invasive carcinoma are subtle, with few consistent changes and no association with phenotype. Conclusion We propose that the early lesions carry the important genetic changes that reflect the major phenotypic information, while additional genetic changes that accumulate in the invasive carcinoma are less associated with the overall phenotype.